{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:48:48Z","timestamp":1780397328104,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jval.2024.08.009","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T17:08:55Z","timestamp":1728407335000},"page":"116-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Challenges in Value Assessment for One-Time Gene Therapies for Inherited Retinal Diseases: Are We Turning a Blind Eye?"],"prefix":"10.1016","volume":"28","author":[{"given":"Jake","family":"Hitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Denee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Brassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Steuten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jval.2024.08.009_bib1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2217\/rme-2016-0010","article-title":"Gene therapies: the challenge of super-high-cost treatments and how to pay for them","volume":"11","author":"Carr","year":"2016","journal-title":"Regen Med"},{"issue":"4","key":"10.1016\/j.jval.2024.08.009_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.drudis.2019.01.019","article-title":"Luxturna: FDA documents reveal the value of a costly gene therapy","volume":"24","author":"Darrow","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jval.2024.08.009_bib3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/CEOR.S297287","article-title":"The burden of X-linked retinitis pigmentosa on patients and society: a narrative literature review","volume":"13","author":"Chivers","year":"2021","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.jval.2024.08.009_bib4","series-title":"Atlas of Inherited Retinal Diseases","first-page":"31","article-title":"X-linked retinitis pigmentosa","author":"Tsang","year":"2018"},{"issue":"8","key":"10.1016\/j.jval.2024.08.009_bib5","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/bjophthalmol-2015-307698","article-title":"RPGR-associated retinopathy: clinical features, molecular genetics, animal models and therapeutic options","volume":"100","author":"Tee","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.jval.2024.08.009_bib6","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041280","article-title":"RPGR-related retinopathy: clinical features, Molecular Genetics, and gene replacement therapy","volume":"13","author":"Awadh Hashem","year":"2023","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.jval.2024.08.009_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/IIO.0000000000000384","article-title":"Gene therapy in X-linked retinitis pigmentosa because of defects in RPGR","volume":"61","author":"Georgiou","year":"2021","journal-title":"Int Ophthalmol Clin"},{"issue":"3","key":"10.1016\/j.jval.2024.08.009_bib8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ceo.13917","article-title":"Inherited retinal diseases: therapeutics, clinical trials and end points-A review","volume":"49","author":"Georgiou","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jval.2024.08.009_bib9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/OPTH.S241928","article-title":"The impact of inherited retinal diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a cost-of-illness perspective","volume":"14","author":"Galvin","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jval.2024.08.009_bib10","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.2147\/OPTH.S313719","article-title":"The impact of inherited retinal diseases in the United States of America (US) and Canada from a cost-of-illness perspective","volume":"15","author":"Gong","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jval.2024.08.009_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajo.2021.08.009","article-title":"Challenges of cost-effectiveness analyses of novel therapeutics for inherited retinal diseases","volume":"235","author":"Jayasundera","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.jval.2024.08.009_bib12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","article-title":"Discounting in economic evaluations","volume":"36","author":"Attema","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2024.08.009_bib14","first-page":"414","article-title":"Narrative reviews: flexible, rigorous, and practical","volume":"14","author":"Sukhera","year":"2022","journal-title":"J\u00a0Grad Med Educ"},{"issue":"2","key":"10.1016\/j.jval.2024.08.009_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care\u2014a health economics approach: an ISPOR special task force [Report] [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2024.08.009_bib18","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jval.2021.04.1284","article-title":"Quantifying value of hope","volume":"24","author":"Reed","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2024.08.009_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CEOR.S385094","article-title":"Elicitation of health state utility values in retinitis pigmentosa by time trade-off in the United Kingdom","volume":"15","author":"O\u2019Brien","year":"2023","journal-title":"CEOR"},{"issue":"1","key":"10.1016\/j.jval.2024.08.009_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100106","article-title":"Patient-reported health-related quality of life in individuals with inherited retinal diseases","volume":"2","author":"Schofield","year":"2022","journal-title":"Ophthalmol Sci"},{"issue":"4","key":"10.1016\/j.jval.2024.08.009_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40273-021-01003-y","article-title":"Methodological challenges in the economic evaluation of a gene therapy for RPE65-mediated inherited retinal disease: the value of vision","volume":"39","author":"Huygens","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2024.08.009_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40123-022-00602-y","article-title":"X-linked retinitis pigmentosa gene therapy: preclinical aspects","volume":"12","author":"Mansouri","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jval.2024.08.009_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2017.01.014","article-title":"Prevalence, age at diagnosis, mortality, and cause of death in retinitis pigmentosa in Korea-a nationwide population-based study","volume":"176","author":"Na","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jval.2024.08.009_bib24","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","article-title":"The Lancet global health Commission on global eye health: vision beyond 2020","volume":"9","author":"Burton","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jval.2024.08.009_bib25","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2147\/OPTH.S365486","article-title":"Retinitis pigmentosa: burden of disease and current unmet needs","volume":"16","author":"Cross","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.jval.2024.08.009_bib27","first-page":"3378","article-title":"Impacts of X-linked retinitis pigmentosa and patient pathways in European Countries: results from the cross-sectional","volume":"41","author":"Pungor","year":"2024","journal-title":"EXPLORE XLRP-1 physician survey"},{"issue":"5","key":"10.1016\/j.jval.2024.08.009_bib28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/13816810.2022.2089359","article-title":"Childhood-onset retinal dystrophies reduces lifetime income by one third - an individual based socio-economic analysis","volume":"43","author":"Kessel","year":"2022","journal-title":"Ophthal Genet"},{"issue":"12","key":"10.1016\/j.jval.2024.08.009_bib29","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jval.2019.07.012","article-title":"Equity weights for priority setting in healthcare: severity, age, or both?","volume":"22","author":"Reckers-Droog","year":"2019","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2024.08.009_bib30","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jval.2021.01.012","article-title":"Willingness to pay for health-related quality of life gains in relation to disease severity and the age of patients","volume":"24","author":"Reckers-Droog","year":"2021","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2024.08.009_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12325-022-02359-z","article-title":"Valuation of treatments for rare diseases: a systematic literature review of societal preference studies","volume":"40","author":"Dabbous","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.jval.2024.08.009_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpubeco.2016.11.012","article-title":"The insurance value of medical innovation","volume":"145","author":"Lakdawalla","year":"2017","journal-title":"J\u00a0Public Econ"},{"key":"10.1016\/j.jval.2024.08.009_bib33","article-title":"Value frameworks for rare diseases: should they be different?","author":"Jena","year":"2017","journal-title":"Health Affairs Blog"},{"issue":"6","key":"10.1016\/j.jval.2024.08.009_bib34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jval.2019.03.012","article-title":"Analytic considerations in applying a general economic evaluation reference case to gene therapy","volume":"22","author":"Drummond","year":"2019","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.08.009_bib35","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1017\/S0266462322000150","article-title":"Should we pay for scientific knowledge spillovers? The underappreciated value of \u201cfailed\u201d R&D efforts","volume":"38","author":"Xie","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.jval.2024.08.009_bib36","article-title":"Health economic evaluation of gene replacement therapies: methodological issues and recommendations","volume":"8","author":"Aball\u00e9a","year":"2020","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"12","key":"10.1016\/j.jval.2024.08.009_bib37","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.ymthe.2018.10.017","article-title":"Addressing the value of gene therapy and enhancing patient access to transformative treatments","volume":"26","author":"Salzman","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jval.2024.08.009_bib38","unstructured":"Michaelides M, Xu J, Wang D, et\u00a0al. AAV5-RPGR (botaretigene sparoparvovec) gene therapy for X-linked retinitis pigmentosa (XLRP) demonstrates localized improvements in static perimetry. Presented at: ARVO Annual Meeting. Denver, CO; December 12,\u00a02022."},{"key":"10.1016\/j.jval.2024.08.009_bib43","first-page":"72","article-title":"Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health","volume":"7","author":"Culyer","year":"2018","journal-title":"Who decides? Who pays?"},{"issue":"8","key":"10.1016\/j.jval.2024.08.009_bib44","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/OPX.0000000000000005","article-title":"Responsiveness of the EQ-5D to the effects of low vision rehabilitation","volume":"90","author":"Malkin","year":"2013","journal-title":"Optom Vis Sci"},{"issue":"7","key":"10.1016\/j.jval.2024.08.009_bib45","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s11136-009-9499-6","article-title":"Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration","volume":"18","author":"Payakachat","year":"2009","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.jval.2024.08.009_bib46","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/09286586.2016.1257027","article-title":"Multivariable regression model of the EuroQol 5-dimension questionnaire in patients seeking outpatient low vision rehabilitation","volume":"24","author":"Malkin","year":"2017","journal-title":"Ophthal Epidemiol"},{"issue":"9","key":"10.1016\/j.jval.2024.08.009_bib51","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s10198-022-01445-x","article-title":"A\u00a0comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots","volume":"23","author":"Khorasani","year":"2022","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2024.08.009_bib52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/hec.1612","article-title":"Discounting and decision making in the economic evaluation of health-care technologies","volume":"20","author":"Claxton","year":"2011","journal-title":"Health Econ"},{"issue":"2","key":"10.1016\/j.jval.2024.08.009_bib53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40273-020-00990-8","article-title":"NICE\u2019s discounting review: clear thinking on rational revision meets obstacle of industrial interests","volume":"39","author":"O\u2019Mahony","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2024.08.009_bib54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s41669-020-00250-7","article-title":"National healthcare economic evaluation guidelines: a cross-country comparison","volume":"5","author":"Sharma","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"10","key":"10.1016\/j.jval.2024.08.009_bib55","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jval.2018.08.005","article-title":"Economic analysis of vaccination programs: an ISPOR good practices for outcomes research task force report","volume":"21","author":"Mauskopf","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.08.009_bib56","article-title":"How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future","volume":"8","author":"Standaert","year":"2020","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"2","key":"10.1016\/j.jval.2024.08.009_bib57","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jval.2020.10.003","article-title":"Health technology assessment with diminishing returns to health: the generalized risk-adjusted cost-effectiveness (GRACE) approach","volume":"24","author":"Lakdawalla","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2024.08.009_bib58","author":"Lakdawalla"},{"issue":"9","key":"10.1016\/j.jval.2024.08.009_bib59","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40273-022-01164-4","article-title":"Carers\u2019 health-related quality of life in global health technology assessment: guidance, case studies and recommendations","volume":"40","author":"Pennington","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.jval.2024.08.009_bib60","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jval.2020.05.017","article-title":"Inclusion of carer health-related quality of life in National Institute for Health and Care Excellence appraisals","volume":"23","author":"Pennington","year":"2020","journal-title":"Value Health"},{"issue":"7514","key":"10.1016\/j.jval.2024.08.009_bib61","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/bmj.331.7514.446","article-title":"Need for differential discounting of costs and health effects in cost effectiveness analyses","volume":"331","author":"Brouwer","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2024.08.009_bib62","author":"Paulden"},{"issue":"2","key":"10.1016\/j.jval.2024.08.009_bib63","article-title":"A\u00a0systematic review of discounting in national health economic evaluation guidelines: healthcare value implications","volume":"12","author":"Williams","year":"2023","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.jval.2024.08.009_bib66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2415-12-43","article-title":"A\u00a0comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma","volume":"12","author":"Bozzani","year":"2012","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"10.1016\/j.jval.2024.08.009_bib67","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jval.2011.11.031","article-title":"QALY weights for diabetic retinopathy--a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO","volume":"15","author":"Heintz","year":"2012","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2024.08.009_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18090","article-title":"Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: systematic review, statistical modeling and survey","volume":"18","author":"Longworth","year":"2014","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.jval.2024.08.009_bib69","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jval.2014.09.004","article-title":"An exploratory study to test the impact on three \u201cbolt-on\u201d items to the EQ-5D","volume":"18","author":"Yang","year":"2015","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2024.08.009_bib70","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jval.2015.08.002","article-title":"A\u00a0vision \u201cbolt-on\u201d item could increase the discriminatory power of the EQ-5D index score","volume":"18","author":"Luo","year":"2015","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2024.08.009_bib71","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10198-019-01156-w","article-title":"A\u00a0vision \u2018bolt-on\u2019 increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery","volume":"21","author":"Gandhi","year":"2020","journal-title":"Eur J Health Econ"},{"issue":"10","key":"10.1016\/j.jval.2024.08.009_bib72","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jval.2017.06.002","article-title":"An exploratory study on using principal-component analysis and confirmatory factor analysis to identify bolt-on dimensions: the EQ-5D case study","volume":"20","author":"Finch","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2024.08.009_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/frhs.2023.1055471","article-title":"A\u00a0theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approach","volume":"3","author":"Berdud","year":"2023","journal-title":"Front Health Serv"},{"key":"10.1016\/j.jval.2024.08.009_bib74","author":"Besley"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524028584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524028584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T23:14:32Z","timestamp":1739229272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524028584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1098301524028584"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.08.009","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in Value Assessment for One-Time Gene Therapies for Inherited Retinal Diseases: Are We Turning a Blind Eye?","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}